PLoS ONE (Jan 2013)

RasGRPs are targets of the anti-cancer agent ingenol-3-angelate.

  • Xiaohua Song,
  • Ana Lopez-Campistrous,
  • Lucy Sun,
  • Nancy A Dower,
  • Noemi Kedei,
  • Jing Yang,
  • Jessica S Kelsey,
  • Nancy E Lewin,
  • Tim E Esch,
  • Peter M Blumberg,
  • James C Stone

DOI
https://doi.org/10.1371/journal.pone.0072331
Journal volume & issue
Vol. 8, no. 8
p. e72331

Abstract

Read online

Ingenol-3-angelate (I3A) is a non-tumor promoting phorbol ester-like compound identified in the sap of Euphoria peplus. Similar to tumor promoting phorbol esters, I3A is a diacylglycerol (DAG) analogue that binds with high affinity to the C1 domains of PKCs, recruits PKCs to cellular membranes and promotes enzyme activation. Numerous anti-cancer activities have been attributed to I3A and ascribed to I3A's effects on PKCs. We show here that I3A also binds to and activates members of the RasGRP family of Ras activators leading to robust elevation of Ras-GTP and engagement of the Raf-Mek-Erk kinase cascade. In response to I3A, recombinant proteins consisting of GFP fused separately to full-length RasGRP1 and RasGRP3 were rapidly recruited to cell membranes, consistent with direct binding of the compound to RasGRP's C1 domain. In the case of RasGRP3, IA3 treatment led to positive regulatory phosphorylation on T133 and activation of the candidate regulatory kinase PKCδ. I3A treatment of select B non-Hodgkin's lymphoma cell lines resulted in quantitative and qualitative changes in Bcl-2 family member proteins and induction of apoptosis, as previously demonstrated with the DAG analogue bryostatin 1 and its synthetic analogue pico. Our results offer further insights into the anticancer properties of I3A, support the idea that RasGRPs represent potential cancer therapeutic targets along with PKC, and expand the known range of ligands for RasGRP regulation.